Capital Group Private Markets

Capital Group Private Markets, established in 1992, is a prominent player in emerging markets private equity, having invested over $5 billion in 80+ companies through its six private equity funds. The company adopts a global strategy to develop a diversified emerging markets portfolio. With a focus on Latin America, Capital Group Private Markets has been actively investing in Colombia for more than 15 years, showcasing its expertise and commitment to the region's growth and development.

Nick Chen

Partner

Leonard Kim

Managing Partner

3 past transactions

RealSelf

Series C in 2018
RealSelf, Inc. operates a platform that serves individuals considering elective cosmetic treatments. Founded in 2005 and based in Seattle, Washington, the company aims to enhance transparency in the cosmetic and aesthetic treatment market, which encompasses a diverse range of services from skin treatments to cosmetic surgeries. The platform allows users to access detailed information about various procedures, share personal experiences, and connect with medical providers. RealSelf features contributions from thousands of medical professionals who have answered over two million questions, provided educational videos, and shared patient testimonials, including before and after photos. This community-driven approach helps potential patients make informed decisions about their cosmetic treatment options.

Innovent Biologics

Series E in 2018
Innovent Biologics is a China-based biopharmaceutical company that discovers, develops, manufactures, and commercializes monoclonal antibodies. It operates a platform for antibody therapeutics across oncology, ophthalmology, immunology, and metabolic diseases, with Tyvyt (sintilimab) as its core asset, a PD-1 inhibitor used in first-line and other cancer indications. The company develops a broad pipeline including biosimilars and novel antibodies and provides distribution, consulting, and R&D services. It maintains strategic collaborations with global partners, including a co-development arrangement with MD Anderson Cancer Center and an alliance with Eli Lilly for TYVYT, and has more than 30 collaborations with major pharmaceutical companies. Innovent is listed on the Hong Kong Exchange and maintains manufacturing and development capabilities in China with a growing portfolio of oncology and non-oncology products marketed domestically and internationally.

D1 Stores

Secondary Market in 2016
At TIENDAS D1 we know that the key to differentiation is through the innovation of the articles in our stores and in this way we understand the needs of our customers, for this reason from the beginning of the conception of the products and until the last details are counted. with the perception and endorsement of the same consumer, information that is part of the strategic decisions for the permanent movements of the different categories, this is how we resort to sensory and performance tests of the products D1 Stores was established in 2009 in MedellĂ­n, Antioquia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.